Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Infant Acute Lymphoblastic Leukemia

An acute lymphoblastic leukemia that occurs in infancy.
National Institutes of Health

Related topics

Related topics

13 relations
Atypical lymphocyteBone MarrowHematopoietic and Lymphoid CellHematopoietic and Lymphoid Tissue
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.
Gene expression profiling was performed on 97 cases of infant ALL from Children's Oncology Group Trial P9407. Statistical… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2009
Highly Cited
2009
Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
MLL-rearranged infant acute lymphoblastic leukemia (ALL) remains the most aggressive type of childhood leukemia, displaying a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2006
Highly Cited
2006
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.
Infant acute lymphoblastic leukemia (ALL) has a poor therapeutic outcome despite attempts to treat it based on prognostic factor… Expand
Highly Cited
2005
Highly Cited
2005
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Acute lymphoblastic leukemia (ALL) in infants is characterized by rearrangements of the mixed lineage leukemia (MLL) gene, drug… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Highly Cited
2004
Highly Cited
2004
Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation.
Forty-four infants with acute lymphoblastic leukemia (ALL) characterized by MLL gene rearrangements were treated on a protocol of… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2003
Highly Cited
2003
Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of mixed lineage leukemia (MLL) gene… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Highly Cited
1999
Highly Cited
1999
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
To define prognostic factors in infant acute lymphoblastic leukemia (ALL), the outcome of 106 infants (age </=12 months) during 3… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
1999
Highly Cited
1999
Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia.
Ikaros, a zinc finger-containing DNA-binding protein, is required for normal lymphocyte development, and germline mutant mice… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
1997
Highly Cited
1997
Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493).
PURPOSE Despite improved event-free survival of older children with acute lymphocytic leukemia (ALL), infants <1 year of age… Expand
Highly Cited
1993
Highly Cited
1993
Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome.
Acute lymphoblastic leukemia (ALL) in infants generally shows distinctive biologic features and has a poor prognosis. Cytogenetic… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE